Genmab stock surges 9% following positive phase 3 ovarian cancer trial results

What happened: Genmab A/S (NASDAQ: GMAB) reported positive top-line results from its Phase 3 RAINFOL-02 trial of rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer, and its shares rose 9%. Key numbers: 584 patients in the Why it matters: The study met both its primary progression-free survival endpoint and key secondary overall survival endpoint with statistically significant improvements over chemotherapy. Corcept's rival treatment Lifyorli (relacorilant) saw its shares fall in contrasting sector movement. Genmab plans to discuss approval pathways with regulators. Market: -19.0% today ($87.10), +128.0% YTD, 2.8x vol — as of 19:17 UTC

Genmab A/S (NASDAQ: GMAB) reported positive top-line results from its Phase 3 RAINFOL-02 trial of rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer, and its shares rose 9%.

The study met both its primary progression-free survival endpoint and key secondary overall survival endpoint with statistically significant improvements over chemotherapy. Corcept's rival treatment Lifyorli (relacorilant) saw its shares fall in contrasting sector movement. Genmab plans to discuss approval pathways with regulators. Market: -19.0% today ($87.10), +128.0% YTD, 2.8x vol — as of 19:17 UTC